Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer

BACKGROUND: Maintenance therapy is important in advanced/metastatic non-small cell lung cancer (NSCLC). Erlotinib as switch maintenance following platinum-based chemotherapy increases survival. Cross-talk between the epidermal growth factor receptor and insulin-like growth factor receptor (IGFR) pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciuleanu, Tudor-Eliade, Ahmed, Samreen, Kim, Joo-Hang, Mezger, Jörg, Park, Keunchil, Thomas, Michael, Chen, Jihong, Poondru, Srinivasu, VanTornout, Jan M, Whitcomb, Debbie, Blackhall, Fiona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589984/
https://www.ncbi.nlm.nih.gov/pubmed/28772281
http://dx.doi.org/10.1038/bjc.2017.226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589984/
https://www.ncbi.nlm.nih.gov/pubmed/28772281
http://dx.doi.org/10.1038/bjc.2017.226

Ejemplares similares